Wen-Hung Chung,
Director, Whole-Genome Research Core Laboratory of Human Diseases,
Chang Gung Memorial Hospital
Dr. Chung has served as a dermatologist at Chang Gung Memorial Hospital, Taiwan since 1999 and in 2008 he further received his Ph.D. degree from the Taiwan International Graduate Program of Academia Sinica and National Yang Ming University. Dr. Chung is a physician of dermatology and a specialist of the field in severe cutaneous adverse drug reactions and cutaneous immunologic disorders. He currently serves as director of department of dermatology and drug hypersensitivity clinical and research center at Taipei & Linkou Chang Gung Memorial Hospital. Dr. Chung has devoted himself into the investigation of severe adverse drug reactions (SCARs) for over a decade and his devotion and findings have great impact in clinic. Dr. Chung and his team has identified genetic and bio-markers for SCARs. He identified strong genetic association of HLA-B*1502 with carbamazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and HLA-B*5801 with allopurinol-SCARs. In addition, he also discovered granulysin as the major mediator for the extensive keratinocyte death in SJS or TEN. These important breakthroughs had been published on Nature and Nature Medicine in 2004 and 2008, respectively. Currently, these markers have been used in clinic before prescription of carbamazepine and allopurinol to prevent patients from the development of SCARs. Since these contributions, Dr. Chung had received awards of the 2006 Top 10 Rising Stars in Taiwan, 2009 the 47th Ten Outstanding Young Persons in Taiwan, and 2011 the International League of Dermatological Societies (ILDS) Young Dermatologist International Achievement Award. Dr. Chung continues his research as well as clinical works for patients with SCARs. In 2012, he establishes the first drug hypersensitivity clinical and research center in Taiwan which receives referral cases of SCARs from all over Taiwan.
Use of High-Throughput Sequencing for Disease Gene Discovery: the Path from Helix to Health
Friday, 2 December 2016 at 15:00
Add to Calendar ▼2016-12-02 15:00:002016-12-02 16:00:00Europe/LondonUse of High-Throughput Sequencing for Disease Gene Discovery: the Path from Helix to HealthNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Although array-based genotyping methods for common variants have thus far succeeded in explaining a modest fraction of the genetic components of human diseases, recent advances in next-generation sequencing (NGS) technologies have rapidly facilitated substantial progress. This outcome is expected because NGS can directly identify the causal variants whereas chip-based platforms generally only capture a few percent of the estimated heritability for these diseases. With further developments in sequencing technologies for data acquisition and more effective tools for data analysis and clinical extraction, NGS now becomes technically feasible to search for Mendelian disease genes in an unbiased manner with strategies that depends on the availability of well-phenotyped patients and family members. Here, we show our attempts to uncover novel disease-causing mutations for rare hereditary diseases (e.g. hereditarily cutaneous diseases, rare neurological diseases, and inherited pediatric conditions) by whole-genome or whole-exome sequencing. In particular, we apply a more comprehensive approach to detect rare variants that contribute considerably to these conditions. Through unveiling the genetic basis of these disorders and the identification of new genes and pathways, a better understanding of disease pathogenesis is obtained, ultimately leading to the development of therapeutic strategies and accurate prediction of clinical outcome.
Add to Calendar ▼2016-12-01 00:00:002016-12-02 00:00:00Europe/LondonNext Generation Sequencing Asia 2016: Clinical ApplicationsNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-12-02 15:00:002016-12-02 16:00:00Europe/LondonUse of High-Throughput Sequencing for Disease Gene Discovery: the Path from Helix to HealthNext Generation Sequencing Asia 2016: Clinical Applications in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
